4D Molecular Therapeutics, Inc. (FDMT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.27B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-446.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.24B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-180.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.22B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $727.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $1.10B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $671.00K.
4D Molecular Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $6.00K | $1.27B | $-446.00K | $-858.00M | $407.66M | 3 month · $5.88M | (m) |
| 2026-03-31 | $0.00 | $5.00K | $1.24B | $-180.00K | $-785.06M | $451.84M | 3 month · $4.45M | (m) |
| 2025-12-31 | $0.00 | $6.00K | $1.22B | $727.00K | $-716.30M | $505.66M | 12 month · $22.02M | (m) |
| 2025-09-30 | $0.00 | $5.00K | $1.10B | $671.00K | $-735.70M | $368.98M | 3 month · $4.52M | (m) |
| 2025-06-30 | $0.00 | $5.00K | $1.10B | $337.00K | $-678.83M | $420.89M | 3 month · $4.96M | (m) |
| 2025-03-31 | $0.00 | $5.00K | $1.09B | $332.00K | $-624.17M | $469.72M | 3 month · $6.99M | (m) |
| 2024-12-31 | $0.00 | $5.00K | $1.09B | $229.00K | $-576.20M | $510.61M | 12 month · $26.12M | (m) |
| 2024-09-30 | $0.00 | $5.00K | $1.08B | $1.08M | $-526.52M | $552.95M | 3 month · $6.49M | (m) |
| 2024-06-30 | $0.00 | $5.00K | $1.07B | $-293.00K | $-482.68M | $588.34M | 3 month · $6.07M | (m) |
| 2024-03-31 | $0.00 | $5.00K | $1.05B | $-109.00K | $-447.73M | $600.56M | 3 month · $5.97M | (m) |
| 2023-12-31 | $0.00 | $4.00K | $723.14M | $16.00K | $-415.33M | $307.83M | 12 month · $19.66M | (m) |
| 2023-09-30 | $0.00 | $4.00K | $712.44M | $534.00K | $-383.04M | $329.93M | 3 month · $4.56M | (m) |
| 2023-06-30 | $0.00 | $4.00K | $697.58M | $345.00K | $-372.79M | $325.14M | 3 month · $4.97M | (m) |
| 2023-03-31 | $0.00 | $3.00K | $562.04M | $-270.00K | $-343.17M | $218.61M | 3 month · $4.22M | (m) |
| 2022-12-31 | $0.00 | $3.00K | $547.02M | $-1.20M | $-314.49M | $231.34M | 12 month · $17.12M | (m) |
| 2022-09-30 | (m) | $3.00K | $540.40M | $-1.85M | $-287.11M | $251.44M | 3 month · $4.52M | (m) |
| 2022-06-30 | (m) | $3.00K | $535.76M | $-1.83M | $-261.42M | $272.52M | 3 month · $4.32M | (m) |
| 2022-03-31 | (m) | $3.00K | $530.81M | $-1.42M | $-233.33M | $296.06M | 3 month · $3.93M | (m) |
| 2021-12-31 | $0.00 | $3.00K | $526.52M | $-423.00K | $-207.00M | $319.11M | 12 month · $13.80M | 12 month · $1.15M |
| 2021-09-30 | $0.00 | $3.00K | $406.24M | $-195.00K | $-181.91M | $224.13M | 3 month · $3.92M | (m) |
| 2021-06-30 | $0.00 | $3.00K | $400.32M | (m) | $-159.67M | $240.65M | 3 month · $3.82M | 3 month · $1.15M |
| 2021-03-31 | $0.00 | $3.00K | $394.51M | (m) | $-152.09M | $242.43M | 3 month · $2.33M | (m) |
| 2020-12-31 | $0.00 | $3.00K | $392.06M | $0.00 | $-135.68M | $256.39M | 12 month · $4.98M | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-105.29M | 3 month · $1.15M | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-99.16M | 3 month · $1.04M | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-85.04M | 3 month · $1.08M | (m) |
| 2019-12-31 | $0.00 | $1.00K | $6.05M | (m) | $-79.03M | $-72.97M | 12 month · $3.54M | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-27.59M | (m) | (m) |
| 2018-05-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $100.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |